Navigation Links
Halozyme Therapeutics to Present at the Jefferies 2011 Global Healthcare Conference on June 9
Date:6/2/2011

SAN DIEGO, June 2, 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced that management will be presenting at the Jefferies 2011 Global Healthcare Conference in New York. The presentation is scheduled for June 9 at 11:00 a.m. EDT (8:00 a.m. PDT). To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the company's Web site at www.halozyme.com. A replay will be available for 90 days after the event.

(Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

About Halozyme

Halozyme Therapeutics is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the insulin, cancer, dermatology and drug delivery markets. The company's product portfolio is based primarily on intellectual property covering the family of human enzymes known as hyaluronidases and additional enzymes that affect the extracellular matrix. Halozyme's Enhanze™ technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. The company has key partnerships with Roche, Baxter and ViroPharma to apply Enhanze technology to therapeutic biologics including Herceptin®, MabThera®, immunoglobulin and Cinryze®. Halozyme's Ultrafast Insulin program combines its rHuPH20 enzyme with mealtime insulins, which may produce more rapid absorption, faster action, and improved glycemic control. The product candidates in Halozyme's pipeline target multiple areas of significant unmet medical need. For more information visit www.halozyme.com.

Halozyme Contact  
Robert H. Uhl
Senior Director, Investor Relations
(858) 704-8264
ruhl@halozyme.com


'/>"/>
SOURCE Halozyme Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Halozyme Therapeutics Reports First Quarter 2011 Financial Results
2. Halozymes Ultrafast Insulin Generates Faster-In and Faster-Out Profile for Type 1 Diabetes Patients Using Insulin Pumps
3. Halozyme Announces Roche Doses First Patient in Phase 3 Clinical Trial With Subcutaneous MabThera® (rituximab)
4. Halozyme Therapeutics Reports Third Quarter 2010 Financial Results
5. Halozyme Receives $5.5 Million Payment From Baxter
6. Halozyme Therapeutics Reports 2008 Third Quarter Financial Results
7. Halozyme Therapeutics Begins Phase 2 Clinical Trial of Insulin With rHuPH20 in Type 1 Diabetic Patients
8. Halozyme Therapeutics Announces Conference Call on November 6 to Review Third Quarter Results
9. Halozyme Therapeutics to Present at Upcoming Investor Conferences
10. Halozyme Therapeutics to Host Research Day for Investors and Analysts
11. Halozyme Therapeutics Appoints Head of Endocrinology Clinical Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... YORK , January 20, 2017 ... Organization, cancer is one of leading causes of death ... 2012. Although the number of cancer related deaths increased ... 1990. Rising in incidence rate of various cancers continues ... to a research report by Global Market Insights, Inc. ...
(Date:1/19/2017)... Jan. 19, 2017  Market Research Future has a half cooked ... Liquid Biopsy is growing rapidly and expected to reach USD 450 ... Highlights ... Liquid Biopsy Market has been assessed as a swiftly growing market ... boom in the coming future. There has been a tremendous growth ...
(Date:1/19/2017)... Research and Markets ... the addition of the "Implantable Biomaterials Market Analysis ... report to their offering. Report Highlights: ... on current and future market trends to identify the investment opportunities ... base numbers Key market trends across the business segments, ...
(Date:1/19/2017)... GAITHERSBURG, Md. , Jan. 19, 2017 /PRNewswire/ ... a privately-held immunotherapeutics company targeting infectious diseases, announced ... the merger of PharmAthene and Altimmune in an ... Fund, HealthCap, Truffle Capital and Redmont Capital. The ... immunotherapeutics company with four clinical stage and one ...
Breaking Biology Technology:
(Date:1/6/2017)... NEWARK, Calif. , Jan. 5, 2017  Delta ... introduced its iris scanning technology for automotive at CES┬« ... GNTX ) to demonstrate the use of ... to identify and authenticate the driver in a car, ... automobiles during the driving experience. Delta ID ...
(Date:12/22/2016)... NEW YORK , December 22, 2016 ... global provider of secure solutions for the e-Government, Public Safety, HealthCare, ... a subsidiary of SuperCom, has been selected to implement and deploy ... county in Northern California , further expanding its ... ...
(Date:12/16/2016)... 16, 2016 Research and Markets has announced ... Global Forecast to 2021" report to their offering. ... The biometric vehicle access ... a CAGR of 14.06% from 2016 to 2021. The market is ... to reach 854.8 Million by 2021. The growth of the biometric ...
Breaking Biology News(10 mins):